research ACNE
58 citations
,
January 1997 in “Dermatologic Clinics” Acne significantly affects mental health and quality of life, with research suggesting hormonal and genetic factors in its development and emphasizing early treatment to prevent scarring.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
3 citations
,
November 2021 in “Frontiers in medicine” Methotrexate effectively controls eye inflammation in Japanese patients with non-infectious uveitis but requires careful monitoring for side effects.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
97 citations
,
January 2006 in “Dermatology” imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
22 citations
,
March 2018 in “American Journal of Clinical Dermatology” Hormonal antiandrogen therapy for acne is underused and can reduce the need for antibiotics.
7 citations
,
January 2017 in “Dermatology Online Journal” TNF-inhibitor induced alopecia can be treated effectively with different therapies.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
22 citations
,
January 2013 in “Journal of The American Academy of Dermatology” Birth control pills can help manage acne, but dermatologists should know their skin-related side effects, especially when prescribing drugs that can harm unborn babies.
October 2024 in “The Journal of Dermatology” Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.
8 citations
,
August 2016 in “Journal of the European Academy of Dermatology and Venereology” Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
August 2001 in “Journal of Cutaneous Medicine and Surgery” Prednisone has risks for lupus patients, isotretinoin is safe for mental health, transplant patients risk skin cancer, and various treatments are effective for specific skin conditions.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
5 citations
,
July 2024 in “Archives of Dermatological Research”
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
July 2025 in “Journal of Investigative Dermatology” 138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
April 2023 in “Journal of Investigative Dermatology” Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
March 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Facial hyperpigmentation improved with oral isotretinoin and ivermectin cream after Demodex mites were identified as the cause.
20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
12 citations
,
August 2020 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.
6 citations
,
April 2021 in “Frontiers in Immunology” A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
25 citations
,
April 2019 in “Journal of The American Academy of Dermatology” Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.